PA8623001A1 - Compuestos de quinolina sustituidos - Google Patents

Compuestos de quinolina sustituidos

Info

Publication number
PA8623001A1
PA8623001A1 PA20058623001A PA8623001A PA8623001A1 PA 8623001 A1 PA8623001 A1 PA 8623001A1 PA 20058623001 A PA20058623001 A PA 20058623001A PA 8623001 A PA8623001 A PA 8623001A PA 8623001 A1 PA8623001 A1 PA 8623001A1
Authority
PA
Panama
Prior art keywords
compounds
substituted quinoline
quinoline compounds
compositions
myn
Prior art date
Application number
PA20058623001A
Other languages
English (en)
Inventor
Peter Bertinato
Derek Lawrence Tickner
Robinson Jr Ralph Pelton
Michael Andre Couturier
Marcus Douglas Ewing
Hamanaka Ernest Sellchi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8623001A1 publication Critical patent/PA8623001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

ESTA INVENCION SE REFIERE A INHIBIDORES DE LA SECRECION DE MTP/APO-B DE FORMULA (I) DONDE R1-R7, X1, M Y N SON COMO SE HAN DEFINIDO EN LA MEMORIA DESCRIPTIVA, ASI COMO A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN LOS COMPUESTOS, Y A PROCEDIMIENTOS DE USO DE LOS COMPUESTOS Y COMPOSICIONES. LOS COMPUESTOS DE LA INVENCION SON UTILES EN EL TRATAMIENTO DE LA OBESIDAD Y ENFERMEDADES, AFECCIONES O TRASTORNOS ASOCIADOS.
PA20058623001A 2004-02-04 2005-02-04 Compuestos de quinolina sustituidos PA8623001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US63376304P 2004-12-06 2004-12-06

Publications (1)

Publication Number Publication Date
PA8623001A1 true PA8623001A1 (es) 2006-03-24

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058623001A PA8623001A1 (es) 2004-02-04 2005-02-04 Compuestos de quinolina sustituidos

Country Status (25)

Country Link
US (3) US7468378B2 (es)
EP (1) EP1716137A1 (es)
JP (1) JP2007520543A (es)
KR (1) KR100799802B1 (es)
AP (1) AP2006003685A0 (es)
AR (1) AR047529A1 (es)
AU (1) AU2005214159A1 (es)
BR (1) BRPI0507462A (es)
CA (1) CA2555133A1 (es)
CO (1) CO5700721A2 (es)
CR (1) CR8544A (es)
EA (1) EA010369B1 (es)
EC (1) ECSP066717A (es)
GE (1) GEP20084360B (es)
IL (2) IL176715A0 (es)
MA (1) MA28347A1 (es)
NL (1) NL1028192C2 (es)
NO (1) NO20063928L (es)
OA (1) OA13365A (es)
PA (1) PA8623001A1 (es)
PE (1) PE20050773A1 (es)
SV (1) SV2007002007A (es)
TW (2) TW200906800A (es)
UY (1) UY28734A1 (es)
WO (1) WO2005080373A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE551339T1 (de) 2003-11-05 2012-04-15 Sarcode Bioscience Inc Modulatoren der zellulären adhäsion
BRPI0507462A (pt) * 2004-02-04 2007-07-10 Pfizer Prod Inc compostos de quinolina substituìdos
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
EP1740553A1 (en) * 2004-04-14 2007-01-10 AstraZeneca AB Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibithors
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
KR20080015792A (ko) 2005-04-19 2008-02-20 서피스 로직스, 인크. 미소체 트리글리세리드 전달 단백질 및 ａｐｏ－ｂ 분비의저해
WO2008050199A2 (en) * 2006-10-23 2008-05-02 Pfizer Japan Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
MX2009004314A (es) 2006-11-13 2009-05-05 Pfizer Prod Inc Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
WO2008097471A1 (en) * 2007-02-02 2008-08-14 Shivvers Steve D High efficiency drier with multi stage heating and drying zones
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
CA3105972A1 (en) * 2007-10-19 2009-04-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
WO2010018547A1 (en) * 2008-08-13 2010-02-18 Pfizer Inc. Aminoquinoline compounds
WO2012177896A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
US8710043B2 (en) 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
ES2552989T3 (es) * 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2015121877A2 (en) * 2014-02-17 2015-08-20 Hetero Research Foundation Polymorphs of lomitapide and its salts
LT3203840T (lt) 2014-10-06 2020-10-26 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai
WO2016055934A1 (en) * 2014-10-09 2016-04-14 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3812379A1 (en) 2016-12-09 2021-04-28 Vertex Pharmaceuticals Incorporated Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
IE52630B1 (en) 1981-03-11 1988-01-06 Wellcome Found Substituted biphenyl compounds
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
CA2091102C (en) 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE69533408T2 (de) 1994-05-27 2005-09-08 Glaxosmithkline S.P.A. Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
MX9709914A (es) 1995-06-07 1998-03-31 Pfizer Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos.
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
JP2000510865A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンカルボキサミド
EP1019378B1 (en) 1996-07-01 2004-09-29 Eli Lilly And Company Hypoglycemic and hypolipidemic compounds
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
AU5513298A (en) 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
JP2001526265A (ja) 1997-12-22 2001-12-18 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての４−ヒドロキシキノリン−３−カルボキサミドおよびヒドラジド
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
IL139449A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US20020032238A1 (en) 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
IL155196A0 (en) 2000-10-05 2003-11-23 Fujisawa Pharmaceutical Co Benzamide derivatives and pharmaceutical compositions containing the same
CN1880304B (zh) 2001-06-28 2010-11-24 辉瑞产品公司 三酰胺取代的吲哚、苯并呋喃及苯并噻吩
RU2004115737A (ru) * 2001-10-25 2005-10-10 Такеда Кемикал Индастриз, Лтд. (JP) Соединение хинолина
CA2468989A1 (en) * 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
US20030162788A1 (en) 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
RU2293721C2 (ru) 2002-02-28 2007-02-20 Джапан Тобакко Инк. Сложноэфирные соединения и их применение в медицине
AU2003286311A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
AU2003286347A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
BRPI0507462A (pt) * 2004-02-04 2007-07-10 Pfizer Prod Inc compostos de quinolina substituìdos

Also Published As

Publication number Publication date
AR047529A1 (es) 2006-01-25
GEP20084360B (en) 2008-04-29
KR100799802B1 (ko) 2008-01-31
US20070093525A1 (en) 2007-04-26
TW200906800A (en) 2009-02-16
AU2005214159A1 (en) 2005-09-01
EP1716137A1 (en) 2006-11-02
CA2555133A1 (en) 2005-09-01
NL1028192C2 (nl) 2006-05-30
CO5700721A2 (es) 2006-11-30
IL176715A0 (en) 2006-10-31
CR8544A (es) 2006-11-30
BRPI0507462A (pt) 2007-07-10
AP2006003685A0 (en) 2006-08-31
EA010369B1 (ru) 2008-08-29
US7368573B2 (en) 2008-05-06
OA13365A (en) 2007-04-13
EA200601239A1 (ru) 2007-02-27
NO20063928L (no) 2006-10-31
NL1028192A1 (nl) 2005-08-08
IL208963A0 (en) 2011-07-31
TWI306454B (en) 2009-02-21
TW200533354A (en) 2005-10-16
US20050234099A1 (en) 2005-10-20
PE20050773A1 (es) 2005-10-26
UY28734A1 (es) 2005-09-30
SV2007002007A (es) 2007-03-20
JP2007520543A (ja) 2007-07-26
US20060223851A1 (en) 2006-10-05
US7468378B2 (en) 2008-12-23
KR20060127123A (ko) 2006-12-11
WO2005080373A1 (en) 2005-09-01
ECSP066717A (es) 2006-10-31
MA28347A1 (fr) 2006-12-01
US7393958B2 (en) 2008-07-01

Similar Documents

Publication Publication Date Title
PA8623001A1 (es) Compuestos de quinolina sustituidos
UY28945A1 (es) Derivados de pirrolopiridina
CR9834A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
HN2009001131A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolinas sustituidas de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
UY27939A1 (es) Compuestos
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
GT200500310A (es) Compuestos organicos
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
PA8514901A1 (es) Metabolitos agonistas/antagonistas de estrogeno
PA8657701A1 (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
HN2003000104A (es) Derivados de ciclopenteno
CR9787A (es) Derivados de imidazopiridina como ligandos del receptor de canabinoides
GT200500016A (es) Compuestos de quinolina sustituidos
BRPI0510503A (pt) compostos e composições como inibidores de catepsina s
DOP2005000015A (es) Compuestos de quinolina sustituidos